130 related articles for article (PubMed ID: 32207204)
41. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
42. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
43. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
[TBL] [Abstract][Full Text] [Related]
44. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.
Russo P; O'Brien MF
Urol Clin North Am; 2008 Nov; 35(4):679-86; viii. PubMed ID: 18992621
[TBL] [Abstract][Full Text] [Related]
45. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
46. A Novel Predictor of Survival with Renal Cell Carcinoma After Nephrectomy.
Peng D; He ZS; Li XS; Tang Q; Zhang L; Yang KW; Yu XT; Zhang CJ; Zhou LQ
J Endourol; 2017 Apr; 31(4):397-404. PubMed ID: 28121179
[TBL] [Abstract][Full Text] [Related]
47. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules.
Adibi M; Kenney PA; Thomas AZ; Borregales LD; Nogueras-González GM; Wang X; Devine CE; Karam JA; Wood CG
Eur Urol; 2016 Feb; 69(2):352-60. PubMed ID: 26382085
[TBL] [Abstract][Full Text] [Related]
48. Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Kwon T; Lee JL; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
J Surg Oncol; 2014 Aug; 110(2):145-50. PubMed ID: 24706355
[TBL] [Abstract][Full Text] [Related]
49. Oncological and functional outcomes after radical nephrectomy for renal cell carcinoma: a comprehensive analysis of prognostic factors.
Sejima T; Iwamoto H; Masago T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Int J Urol; 2013 Apr; 20(4):382-9. PubMed ID: 23003206
[TBL] [Abstract][Full Text] [Related]
50. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
[TBL] [Abstract][Full Text] [Related]
51. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
[TBL] [Abstract][Full Text] [Related]
52. Bilateral Synchronous Sporadic Renal Cell Carcinoma: Retroperitoneoscopic Strategies and Intermediate Outcomes of 60 Patients.
Wang B; Gong H; Zhang X; Li H; Ma X; Song E; Gao J; Dong J
PLoS One; 2016; 11(5):e0154578. PubMed ID: 27136191
[TBL] [Abstract][Full Text] [Related]
53. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma.
Gu L; Ma X; Xie Y; Li H; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
Clin Genitourin Cancer; 2017 Jun; 15(3):e369-e377. PubMed ID: 28038932
[TBL] [Abstract][Full Text] [Related]
54. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
55. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Significance of Preoperative Prognostic Nutritional Index in Patients Undergoing Nephrectomy for Nonmetastatic Renal Cell Carcinoma.
Kim SJ; Kim SI; Cho DS
Am J Clin Oncol; 2020 Jun; 43(6):388-392. PubMed ID: 32079852
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
58. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy.
Yoon HJ; Paeng JC; Kwak C; Park YH; Kim TM; Lee SH; Chung JK; Edmund Kim E; Lee DS
Ann Nucl Med; 2013 Oct; 27(8):748-55. PubMed ID: 23818007
[TBL] [Abstract][Full Text] [Related]
59. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
60. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
